Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2006

View Archived Issues

Leuprolide beneficial in phase II Alzheimer's disease study

Phase II studies show anemia correction with CERA in chronic kidney disease

Phase IIa study of LAB CGRP begins enrollment

Chimerix signs CRADA with U.S. Army for smallpox therapeutic CMX-001

Enrollment begins in phase III Bronchitol study

Vectura to work with Boehringer Ingelheim on dry powder inhaler

CEL-1000 shows adjuvant activity with malaria vaccines

ACP-103 increases slow wave sleep in clinical study

Pilot study of MM-093 in psoriasis completes enrollment

Bio-E-Gel NDA accepted for review

End of phase II testing of diquafosol in Asia triggers milestone payment

Enrollment completed in pivotal study of IL-Trap for CAPS

Stressgen to focus on reformulated HspE7

NIAID funds development of VivaGel for genital herpes

New evidence that selective M3 muscarinic antagonists can inhibit tumor growth

Feeding-suppressive properties of new orally active NPY Y5 antagonist

Antiangiogenic efficacy of a new multiple RTK inhibitor from Roche

Endocyte investigates folate-targeted cytotoxic anticancer drug in phase I study

Meditor begins phase II trial for MTR-104 in intradialytic hypotension

Yaz now available

Alteon and HaptoGuard to merge

Takeda and Lilly conclude U.S. Actos marketing collaboration

Pozen completes SPA for PN-200

European Commission approves Prograf for use in heart transplantation

Recent patents cover therapeutic agents for neurological disorders

Novel treatment options for endocrine-related disorders disclosed in recent patents

Therapeutic agents for cardiovascular disorders disclosed in recent patents

Dual muscarinic M3 receptor antagonists and PDE4 inhibitors potentially effective for COPD

Novel agent for the management of acute renal failure in sepsis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...